# MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

> **NCT04509791** · PHASE2 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 114 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Anti-Human Thymocyte Immunoglobulin, Rabbit

## Key facts

- **NCT ID:** NCT04509791
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2024-12-16
- **Final completion:** 2024-12-16
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04509791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04509791, "MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04509791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*